1021919-30-1

Basic information

• Product Name: 3H-IMidazo[4,5-b]pyridine-3-carboxylicacid,6-broMo-,1,1-diMethylethylester
• Synonyms: 3H-IMidazo[4,5-b]pyridine-3-carboxylicacid,6-broMo-,1,1-diMethylethylester;tert-butyl 6-bromo-3H-imidazo[4,5-b]pyridine-3-carboxylate
• CAS NO: 1021919-30-1
• Molecular Formula: C11H12BrN3O2
• Molecular Weight: 298.13588
• Mol File: 1021919-30-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3H-IMidazo[4,5-b]pyridine-3-carboxylicacid,6-broMo-,1,1-diMethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-IMidazo[4,5-b]pyridine-3-carboxylicacid,6-broMo-,1,1-diMethylethylester(1021919-30-1)
• EPA Substance Registry System: 3H-IMidazo[4,5-b]pyridine-3-carboxylicacid,6-broMo-,1,1-diMethylethylester(1021919-30-1)

Safety Data

• Hazardous Substances Data: 1021919-30-1(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 28279-49-4 6-bromo-3H-imidazo[4,5-b]pyridine 

Relevant articles and documents

Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation

Based on indole scaffold, a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, namely FD223, was developed by the bioisosteric replacement drug discovery approach and studied for the treatment of acute myeloid leukemia (AML). In vitro

HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.